|Day's Range||148.58 - 154.60|
|52 Week Range||36.71 - 192.94|
|PE Ratio (TTM)||-17.50|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Preliminary data highlights breast, ovarian, lung and skin cancer data to presented during the American Society of Clinical Oncology meeting next month.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives TESARO, Inc. a score of 25. Our analysis is based on comparing TESARO, Inc. with the following peers – Clovis Oncology, Inc., ZIOPHARM Oncology, Inc., Amgen Inc., Cerulean Pharma, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Insys Therapeutics, Inc. and Pfizer Inc. (CLVS-US, ZIOP-US, AMGN-US, CERU-US, ... Read more (Read more...)
An analyst upgraded Clovis ahead of a key study for its ovarian cancer drug, which he said holds up against another from AstraZeneca.